Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Genentech licenses Relay’s SHP2 inhibitor
by Lisa M. Jarvis
December 17, 2020
| A version of this story appeared in
Volume 98, Issue 48
Genentech will pay $75 million to license RLY-1971, Relay Therapeutics’ SHP2 inhibitor, which is in a Phase 1 trial to treat solid tumors. The deal gives Genentech access to a promising partner for its experimental inhibitor of KRAS G12C, a notoriously difficult target for cancer drugs. SHP2 helps KRAS cycle between its “on” and “off” states, and researchers think dampening its effects could increase the efficacy of KRAS inhibitors, which bind to the protein’s “off” state.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X